Compare FTCI & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | KRRO |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | 87 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 109.7M |
| IPO Year | 2021 | 2019 |
| Metric | FTCI | KRRO |
|---|---|---|
| Price | $4.53 | $10.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $10.80 | ★ $34.80 |
| AVG Volume (30 Days) | 146.0K | ★ 207.0K |
| Earning Date | 03-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,355,000.00 | $6,392,000.00 |
| Revenue This Year | $89.54 | N/A |
| Revenue Next Year | $36.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $2.13 | $5.20 |
| 52 Week High | $12.75 | $55.89 |
| Indicator | FTCI | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 43.60 |
| Support Level | $4.07 | $10.55 |
| Resistance Level | $5.20 | $14.96 |
| Average True Range (ATR) | 0.54 | 0.89 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 13.30 | 6.50 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.